Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature
Identifieur interne : 002577 ( Ncbi/Merge ); précédent : 002576; suivant : 002578Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature
Auteurs : David G. Addiss [États-Unis] ; Molly A. Brady [États-Unis]Source :
- Filaria Journal [ 1475-2883 ] ; 2007.
Abstract
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) has two major goals: to interrupt transmission of the parasite and to provide care for those who suffer the devastating clinical manifestations of the disease (morbidity control). This latter goal addresses three filariasis-related conditions: acute inflammatory episodes; lymphoedema; and hydrocele. Research during the last decade has confirmed the importance of bacteria as a cause of acute inflammatory episodes in filariasis-endemic areas, known as acute dermatolymphangioadenitis (ADLA). Current lymphoedema management strategies are based on the central role of ADLA as a trigger for lymphoedema progression. Simple intervention packages are in use that have resulted in dramatic reductions in ADLA rates, a lower prevalence of chronic inflammatory cells in the dermis and subdermis, and improvement in quality of life. During the past decade, the socioeconomic impact of ADLA and lymphoedema in filariasis-endemic areas has received increasing attention. Numerous operational research questions remain to be answered regarding how best to optimize, scale up, monitor, and evaluate lymphoedema management programmes. Of the clinical manifestations targeted by the GPELF, hydrocele has been the focus of the least attention. Basic information is lacking on the effectiveness and complications of hydrocele surgery and risk of post-operative hydrocele recurrence in filariasis-endemic areas. Data on the impact of mass administration of antifilarial drugs on filarial morbidity are inconsistent. Several studies report reductions in acute inflammatory episodes, lymphoedema, and/or hydrocele following mass drug administration, but other studies report no such association. Assessing the public health impact of mass treatment with antifilarial drugs is important for programme advocacy and morbidity control strategies. Thus, although our knowledge of filariasis-related morbidity and its treatment has expanded in recent years, much work remains to be done to address the needs of more than 40 million persons who suffer worldwide from these conditions.
Url:
DOI: 10.1186/1475-2883-6-2
PubMed: 17302976
PubMed Central: 1828725
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001D03
- to stream Pmc, to step Curation: 001D02
- to stream Pmc, to step Checkpoint: 003B22
- to stream PubMed, to step Corpus: 003757
- to stream PubMed, to step Curation: 003757
- to stream PubMed, to step Checkpoint: 003757
Links to Exploration step
PMC:1828725Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature</title>
<author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name>
<affiliation wicri:level="1"><nlm:aff id="I1">WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341</wicri:regionArea>
<wicri:noRegion>30341</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="I2">Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009</wicri:regionArea>
<wicri:noRegion>49009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030</wicri:regionArea>
<wicri:noRegion>Georgia 30030</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17302976</idno>
<idno type="pmc">1828725</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828725</idno>
<idno type="RBID">PMC:1828725</idno>
<idno type="doi">10.1186/1475-2883-6-2</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">001D03</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001D03</idno>
<idno type="wicri:Area/Pmc/Curation">001D02</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001D02</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003B22</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003B22</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">003757</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003757</idno>
<idno type="wicri:Area/PubMed/Curation">003757</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003757</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003757</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003757</idno>
<idno type="wicri:Area/Ncbi/Merge">002577</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature</title>
<author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name>
<affiliation wicri:level="1"><nlm:aff id="I1">WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341</wicri:regionArea>
<wicri:noRegion>30341</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="I2">Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009</wicri:regionArea>
<wicri:noRegion>49009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030</wicri:regionArea>
<wicri:noRegion>Georgia 30030</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Filaria Journal</title>
<idno type="eISSN">1475-2883</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The Global Programme to Eliminate Lymphatic Filariasis (GPELF) has two major goals: to interrupt transmission of the parasite and to provide care for those who suffer the devastating clinical manifestations of the disease (morbidity control). This latter goal addresses three filariasis-related conditions: acute inflammatory episodes; lymphoedema; and hydrocele. Research during the last decade has confirmed the importance of bacteria as a cause of acute inflammatory episodes in filariasis-endemic areas, known as acute dermatolymphangioadenitis (ADLA). Current lymphoedema management strategies are based on the central role of ADLA as a trigger for lymphoedema progression. Simple intervention packages are in use that have resulted in dramatic reductions in ADLA rates, a lower prevalence of chronic inflammatory cells in the dermis and subdermis, and improvement in quality of life. During the past decade, the socioeconomic impact of ADLA and lymphoedema in filariasis-endemic areas has received increasing attention. Numerous operational research questions remain to be answered regarding how best to optimize, scale up, monitor, and evaluate lymphoedema management programmes. Of the clinical manifestations targeted by the GPELF, hydrocele has been the focus of the least attention. Basic information is lacking on the effectiveness and complications of hydrocele surgery and risk of post-operative hydrocele recurrence in filariasis-endemic areas. Data on the impact of mass administration of antifilarial drugs on filarial morbidity are inconsistent. Several studies report reductions in acute inflammatory episodes, lymphoedema, and/or hydrocele following mass drug administration, but other studies report no such association. Assessing the public health impact of mass treatment with antifilarial drugs is important for programme advocacy and morbidity control strategies. Thus, although our knowledge of filariasis-related morbidity and its treatment has expanded in recent years, much work remains to be done to address the needs of more than 40 million persons who suffer worldwide from these conditions.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<double pmid="17302976"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature</title>
<author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name>
<affiliation wicri:level="1"><nlm:aff id="I1">WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341</wicri:regionArea>
<wicri:noRegion>30341</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="I2">Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009</wicri:regionArea>
<wicri:noRegion>49009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030</wicri:regionArea>
<wicri:noRegion>Georgia 30030</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17302976</idno>
<idno type="pmc">1828725</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828725</idno>
<idno type="RBID">PMC:1828725</idno>
<idno type="doi">10.1186/1475-2883-6-2</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">001D03</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001D03</idno>
<idno type="wicri:Area/Pmc/Curation">001D02</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001D02</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003B22</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003B22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature</title>
<author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name>
<affiliation wicri:level="1"><nlm:aff id="I1">WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341</wicri:regionArea>
<wicri:noRegion>30341</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="I2">Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Fetzer Institute, 9292 West KL Avenue, Kalamazoo, Michigan, 49009</wicri:regionArea>
<wicri:noRegion>49009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lymphatic Filariasis Support Center, The Task Force for Child Survival and Development, 750 Commerce Dr, Suite 400, Decatur, Georgia 30030</wicri:regionArea>
<wicri:noRegion>Georgia 30030</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Filaria Journal</title>
<idno type="eISSN">1475-2883</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The Global Programme to Eliminate Lymphatic Filariasis (GPELF) has two major goals: to interrupt transmission of the parasite and to provide care for those who suffer the devastating clinical manifestations of the disease (morbidity control). This latter goal addresses three filariasis-related conditions: acute inflammatory episodes; lymphoedema; and hydrocele. Research during the last decade has confirmed the importance of bacteria as a cause of acute inflammatory episodes in filariasis-endemic areas, known as acute dermatolymphangioadenitis (ADLA). Current lymphoedema management strategies are based on the central role of ADLA as a trigger for lymphoedema progression. Simple intervention packages are in use that have resulted in dramatic reductions in ADLA rates, a lower prevalence of chronic inflammatory cells in the dermis and subdermis, and improvement in quality of life. During the past decade, the socioeconomic impact of ADLA and lymphoedema in filariasis-endemic areas has received increasing attention. Numerous operational research questions remain to be answered regarding how best to optimize, scale up, monitor, and evaluate lymphoedema management programmes. Of the clinical manifestations targeted by the GPELF, hydrocele has been the focus of the least attention. Basic information is lacking on the effectiveness and complications of hydrocele surgery and risk of post-operative hydrocele recurrence in filariasis-endemic areas. Data on the impact of mass administration of antifilarial drugs on filarial morbidity are inconsistent. Several studies report reductions in acute inflammatory episodes, lymphoedema, and/or hydrocele following mass drug administration, but other studies report no such association. Assessing the public health impact of mass treatment with antifilarial drugs is important for programme advocacy and morbidity control strategies. Thus, although our knowledge of filariasis-related morbidity and its treatment has expanded in recent years, much work remains to be done to address the needs of more than 40 million persons who suffer worldwide from these conditions.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature.</title>
<author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341, USA. daddiss@fetzer.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341</wicri:regionArea>
<wicri:noRegion>30341</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17302976</idno>
<idno type="pmid">17302976</idno>
<idno type="doi">10.1186/1475-2883-6-2</idno>
<idno type="wicri:Area/PubMed/Corpus">003757</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003757</idno>
<idno type="wicri:Area/PubMed/Curation">003757</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003757</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003757</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003757</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature.</title>
<author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341, USA. daddiss@fetzer.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>WHO Collaborating Center for Control and Elimination of Lymphatic Filariasis in the Americas, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Mailstop F-22, 4770 Buford Highway, Atlanta, Georgia, 30341</wicri:regionArea>
<wicri:noRegion>30341</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
</author>
</analytic>
<series><title level="j">Filaria journal</title>
<idno type="eISSN">1475-2883</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Global Programme to Eliminate Lymphatic Filariasis (GPELF) has two major goals: to interrupt transmission of the parasite and to provide care for those who suffer the devastating clinical manifestations of the disease (morbidity control). This latter goal addresses three filariasis-related conditions: acute inflammatory episodes; lymphoedema; and hydrocele. Research during the last decade has confirmed the importance of bacteria as a cause of acute inflammatory episodes in filariasis-endemic areas, known as acute dermatolymphangioadenitis (ADLA). Current lymphoedema management strategies are based on the central role of ADLA as a trigger for lymphoedema progression. Simple intervention packages are in use that have resulted in dramatic reductions in ADLA rates, a lower prevalence of chronic inflammatory cells in the dermis and subdermis, and improvement in quality of life. During the past decade, the socioeconomic impact of ADLA and lymphoedema in filariasis-endemic areas has received increasing attention. Numerous operational research questions remain to be answered regarding how best to optimize, scale up, monitor, and evaluate lymphoedema management programmes. Of the clinical manifestations targeted by the GPELF, hydrocele has been the focus of the least attention. Basic information is lacking on the effectiveness and complications of hydrocele surgery and risk of post-operative hydrocele recurrence in filariasis-endemic areas. Data on the impact of mass administration of antifilarial drugs on filarial morbidity are inconsistent. Several studies report reductions in acute inflammatory episodes, lymphoedema, and/or hydrocele following mass drug administration, but other studies report no such association. Assessing the public health impact of mass treatment with antifilarial drugs is important for programme advocacy and morbidity control strategies. Thus, although our knowledge of filariasis-related morbidity and its treatment has expanded in recent years, much work remains to be done to address the needs of more than 40 million persons who suffer worldwide from these conditions.</div>
</front>
</TEI>
</pubmed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002577 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002577 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:1828725 |texte= Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17302976" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |